review organ
margin bit light rais po
upsid result strong organ growth
revenu y/i organ includ pass-through
fx estimate y/i organ fx
street y/i adj ebitda y/i margin
our/th street adj ep y/i vs our/th
street first look note link addit detail
 ds organ q/q limit margin expans
strong end base model first quarter post-merg
consolid organ revenu grew high-singl digit un-adjust technolog
analyt solut ta revenu post consecut quarter high-
singl digit organ growth end also encourag see
 ds revenu organ acceler q/q despit
prior-year comparison full-year ds organ fail acceler
organ backlog convers deterior quarterli averag
remind addit ds report
contract win remain focus backlog convers organ revenu trend
evalu iqv next-gen/data-en cro strategi work also cite
 ds organ includ impact pass-through pass-through includ
report backlog revenu figur believ impact growth
also account lastli contact sale medic solut csm
revenu grew organ best quarter yet post-merg seem like csm
growth may deceler base guidanc regard
guidanc adj ebitda guid came expect model
gross margin compress off-set sg leverag result adj ebitda
margin y/i reiter buy
adjust est rais po
rais revenu est stronger ta lower adj ebitda est lower gross
margin maintain adj ep est non-gaap add-back lower tax off-set
lower margin rais po still base adj ep
net dbt
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
ia lead global provid
advanc analyt technolog solut
contract research servic life scienc
industri compani form
merger im health quintil world
seek improv clinic drug develop
commerci healthcar outcom
applic data scienc
posit due compani
differenti grow technolog analyt
solut healthi cro industri fundament
proven track record capit deploy
support growth think deliv mid-
augment double-digit adj ep
growth upcom year
price object base adj ep estim in-lin
averag one-year forward price-to-earnings multipl last five year believ
multipl warrant evolv portfolio recent technolog win rate
cro book help improv growth next year risk soft drug
commerci spend downturn biotech financ technolog data supply/secur
regulatori risk competit execut risk biopharma custom consolid
juan avendano herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
